A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2018
At a glance
- Drugs AMG 757 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Amgen
- 26 Sep 2018 According to the trial design presented at the 19th World Conference on Lung Cancer, extended disease patients with ongoing clinical benefit following not more than 6 cycles of first-line platinum-based chemotherapy will be enrolled in this study.
- 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer.
- 06 Jun 2018 Planned End Date changed from 19 Apr 2021 to 18 Jul 2021.